SCHEMBL21965348

SCHEMBL21965348

CC(C)(C)Oc1c[nH]c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.54
ATM Q13315 1/20 0.48
PBRM1 Q86U86 1/20 0.46
KIF11 P52732 1/20 0.45
GPR84 Q9NQS5 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP3A4 P08684 2/20 0.42
MAPT P10636 2/20 0.42
AHR P35869 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTR2A P28223 2/20 0.42
ADRB1 P08588 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2C P28335 1/20 0.42
HTR1E P28566 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethoxycarbonyl Group SCHEMBL27685883 0.84 SLC22A6 (0.44) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL10920865 0.82 SLC22A6 (0.53) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL28658592 0.81 SLC22A6 (0.50) SLC22A6ATMPBRM1KIF11GPR84
SCHEMBL1899742 0.78 SLC22A6 (0.59) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL3538344 0.77 SLC22A6 (0.58) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL6535531 0.77 SLC22A6 (0.58) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL3801229 0.76 RHEB (0.54) MEN1KMT2ACYP3A4MAPTAHR
SCHEMBL5957996 0.75 SLC22A6 (0.49) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL28167599 0.75 SLC22A6 (0.65) SLC22A6ATMPBRM1GPR84MEN1
SCHEMBL31378042 0.74 SLC22A6 (0.61) SLC22A6ATMPBRM1GPR84MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation CRBN, CBL, STUB1 SLC22A6 4729/4885ATM 2706/4885PBRM1 2178/4885
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBL, STUB1 SLC22A6 4729/4885ATM 2706/4885PBRM1 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.